Evidence map›Paper›PMID 35799873›Full record

ArticleClinical and experimental vaccine research2022

A survey of healthcare workers' recommendations about human papillomavirus vaccination.

Hitomi Nishioka, Tomoko Onishi, Taito Kitano, Masahiro Takeyama, Natsuko Imakita, Kei Kasahara, Ryuji Kawaguchi, Jennifer Akiko Masaki, Keiji Nogami

Abstract read
In one paragraph

Article in Clinical and experimental vaccine research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hitomi NishiokaDepartment of Pediatrics, Nara Prefecture Seiwa Medical Center, Sango, Japan.ORCID https://orcid.org/0000-0003-4871-8495
Tomoko OnishiDepartment of Pediatrics, Nara Medical University, Kashihara, Japan.ORCID https://orcid.org/0000-0002-0199-7645
Taito KitanoDepartment of Pediatrics, Nara Medical University, Kashihara, Japan.ORCID https://orcid.org/0000-0003-0623-066X
Masahiro TakeyamaDepartment of Pediatrics, Nara Medical University, Kashihara, Japan.ORCID https://orcid.org/0000-0002-9348-9815
Natsuko ImakitaCenter for Infectious Diseases, Nara Medical University, Kashihara, Japan.ORCID https://orcid.org/0000-0002-4684-3498
Kei KasaharaCenter for Infectious Diseases, Nara Medical University, Kashihara, Japan.ORCID https://orcid.org/0000-0001-6431-7208
Ryuji KawaguchiDepartment of Obstetrics and Gynecology, Nara Medical University, Kashihara, Japan.ORCID https://orcid.org/0000-0003-4740-9236
Jennifer Akiko MasakiDepartment of Pediatrics, Nara Medical University, Kashihara, Japan.ORCID https://orcid.org/0000-0003-2033-2785
Keiji NogamiDepartment of Pediatrics, Nara Medical University, Kashihara, Japan.ORCID https://orcid.org/0000-0002-2415-2194

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The human papillomavirus (HPV) vaccine is safe and effective for preventing HPV-related diseases. However, HPV vaccination rates in Japan are low because the "Ministry of Health, Labour and Welfare" had stopped recommending vaccination. We assessed healthcare workers' (HCWs) current recommendations regarding the HPV vaccine and how the provision of information about HPV vaccination affected their recommendations. Materials and Methods: A survey was conducted among nurses and physicians in Nara prefecture from March 2021 to July 2021. The questionnaire asked about their understanding, recommendations, and opinions regarding HPV vaccination. Before answering the last two questions (optional), the HCWs read evidence-based information quantifying the risks and benefits of HPV vaccination. Results: A total of 441 HCWs completed the questionnaire. Only 19% of HCWs always recommended HPV vaccination for girls aged 12-16 years. The evidence-based information significantly improved the percentage of HCWs who would "always recommend" vaccination. Conclusion: This study showed that the proportion of HCWs who recommend HPV vaccination to adolescent girls remains low in Japan. However, we found that evidence-based information describing the causal relationship between adverse events and vaccination, quantifying the risks and benefits, noting the importance of HCW communications with families, and reporting the recommendations of national societies, might increase HCWs' recommendations for HPV vaccination.

Indexed as

Healthcare workersHuman papillomavirusSurveyVaccine acceptanceVaccines

Identifiers

PMID35799873
PMCPMC9200650

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.